Literature DB >> 15817481

Modeling and experimental validation of the binary complex of the plectin actin-binding domain and the first pair of fibronectin type III (FNIII) domains of the beta4 integrin.

Sandy H M Litjens1, Kevin Wilhelmsen, José M de Pereda, Anastassis Perrakis, Arnoud Sonnenberg.   

Abstract

The binding of plectin to the beta4 subunit of the alpha6beta4 integrin is a critical step in the formation of hemidesmosomes. An important interaction between these two proteins occurs between the actin-binding domain (ABD) of plectin and the first pair of fibronectin type III (FNIII) domains and a small part of the connecting segment of beta4. Previously, a few amino acids, critical for this interaction, were identified in both plectin and beta4 and mapped on the crystal structures of the ABD of plectin and the first pair of FNIII domains of beta4. In the present study, we used this biochemical information and protein-protein docking calculations to construct a model of the binary complex between these two protein domains. The top scoring computational model predicts that the calponin-homology 1 (CH1) domain of the ABD associates with the first and the second FNIII domains of beta4. Our mutational analysis of the residues at the proposed interface of both the FNIII and the CH1 domains is in agreement with the suggested interaction model. Computational simulations to predict protein motions suggest that the exact model of FNIII and plectin CH1 interaction might well differ in detail from the suggested model due to the conformational plasticity of the FNIII domains, which might lead to a closely related but different mode of interaction with the plectin-ABD. Furthermore, we show that Ser-1325 in the connecting segment of beta4 appears to be essential for the recruitment of plectin into hemidesmosomes in vivo. This is consistent with the proposed model and previously published mutational data. In conclusion, our data support a model in which the CH1 domain of the plectin-ABD associates with the groove between the two FNIII domains of beta4.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15817481     DOI: 10.1074/jbc.M411818200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  The structure of the plakin domain of plectin reveals a non-canonical SH3 domain interacting with its fourth spectrin repeat.

Authors:  Esther Ortega; Rubén M Buey; Arnoud Sonnenberg; José M de Pereda
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

2.  Structural basis of the interaction between integrin alpha6beta4 and plectin at the hemidesmosomes.

Authors:  José M de Pereda; M Pilar Lillo; Arnoud Sonnenberg
Journal:  EMBO J       Date:  2009-02-26       Impact factor: 11.598

3.  Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice.

Authors:  Rui Xu; Sarah DeVries; Marybeth Camboni; Paul T Martin
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

4.  Sarcospan-dependent Akt activation is required for utrophin expression and muscle regeneration.

Authors:  Jamie L Marshall; Johan Holmberg; Eric Chou; Amber C Ocampo; Jennifer Oh; Joy Lee; Angela K Peter; Paul T Martin; Rachelle H Crosbie-Watson
Journal:  J Cell Biol       Date:  2012-06-25       Impact factor: 10.539

5.  An Arf6- and caveolae-dependent pathway links hemidesmosome remodeling and mechanoresponse.

Authors:  Naël Osmani; Julien Pontabry; Jordi Comelles; Nina Fekonja; Jacky G Goetz; Daniel Riveline; Elisabeth Georges-Labouesse; Michel Labouesse
Journal:  Mol Biol Cell       Date:  2017-12-13       Impact factor: 4.138

6.  Sarcospan: a small protein with large potential for Duchenne muscular dystrophy.

Authors:  Jamie L Marshall; Rachelle H Crosbie-Watson
Journal:  Skelet Muscle       Date:  2013-01-03       Impact factor: 4.912

7.  Plectin protects podocytes from adriamycin-induced apoptosis and F-actin cytoskeletal disruption through the integrin α6β4/FAK/p38 MAPK pathway.

Authors:  Yongliang Ni; Xin Wang; Xiaoxuan Yin; Yan Li; Xigao Liu; Haixin Wang; Xiangjv Liu; Jun Zhang; Haiqing Gao; Benkang Shi; Shaohua Zhao
Journal:  J Cell Mol Med       Date:  2018-09-06       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.